Publications

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against P. aeruginosa isolates from 15 European countries and Israel (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Carbapenem-resistant Klebsiella pneumoniae clinical isolate harbouring a blaIMP-4- and qnrS-carrying plasmid, as well as a conjugative blaKPC-2 plasmid, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from European hospitals: Results from the SENTRY Program (2010-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Characterization of intrinsic Beta-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa from USA hospitals, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Linezolid susceptibility surveillance in Europe for 2013: ZAAPS Program (5,076 strains), Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity tested against Gram-positive clinical isolates from European hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity for telavancin, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of daptomycin and comparator agents tested against Methicillin-resistant S. aureus and vancomycin-resistant enterococci: Analysis of five-year trends in Europe and USA hospitals (2009-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae recovered principally from lower respiratory tract specimens in older adult patients (≥50 years of age) in select European countries (2009-2011), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

KPC-producing Pseudomonas aeruginosa from the United States: What is next?, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftolozane/tazobactam activity when tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in European hospitals (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin tested against Gram-positive clinical isolates responsible for documented skin and soft tissue infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Polymyxin B: Can we create a better product?, Lead author: Kassamali, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftobiprole activity tested against bacterial isolates from hospitalized patients with pneumonia in European hospitals and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial Activity of Ceftobiprole Tested against Staphylococci and Streptococci from European Countries and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Current analysis of oritavancin potency when tested against vancomycin-resistant and -susceptible enterococcal clinical isolates recovered from European medical centres (2009-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013) when using a revised susceptibility testing method, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftazidime-avibactam activity tested against select Gram-negative organisms from a global surveillance program (2011) in relation to the ceftazidime epidemiologic cut-off value, Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of solithromycin tested against serotyped macrolide-resistant Streptococcus pneumoniae collected from medical centers across the USA (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Multilocus sequence typing of Mycobacterium xenopi. by Alexander DC, Marras TK, Ma JH, Mirza S, Liu D, Kus JV, Soualhine H, Escuyer V, Warshauer D, Brode SK, Farrell DJ and Jamieson FB published in J. Clin. Microbiol. 2014; 52 (11): 3973-3977

Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. by Sader HS, Castanheira M, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (3): 1684-1692

Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. by Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B and Azie NE published in PLoS One. 2014; 9 (7): e101510

Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada. by Marchand-Austin A, Memari N, Patel SN, Tang P, Deeks SL, Jamieson FB, Crowcroft NS and Farrell DJ published in Int. J. Antimicrob. Agents. 2014; 44 (1): 82-84

Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. by Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ and Patel SN published in Anaerobe. 2014; 28: 120-125

Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 443-448

Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2468-2471

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (7): 3882-3888

Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States. by Castanheira M, Williams G, Jones RN and Sader HS published in Microb. Drug Res. 2014; 20 (5): 436-440

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. by Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 19-25

Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. by Mendes RE, Deshpande LM and Jones RN published in Drug Resist. Updat. 2014; 17 (1-2): 1-12

Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians! by Jones RN, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 91-92

Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011 – 2012): Ceftaroline remains active in vitro among beta-lactam agents. by Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (8): 4923-4927

Amikacin/fosfomycin (5:2 ratio): characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. by Montgomery AB, Rhomberg PR, Abuan T, Walters KA and Flamm RK published in Antimicrob. Agents Chemother. 2014; 58 (7): 3708-3713

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. by Castanheira M, Messer SA, Jones RN, Farrell DJ and Pfaller MA published in Int. J. Antimicrob. Agents. 2014; 44 (4): 320-326

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. by Fernandez-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Florl C and Guarro J published in Antimicrob. Agents Chemother. 2014; 58 (7): 3646-3649

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values by Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Dietrich RR and Jones RN published in Mycopathologia 2014; 178 (1-2): 1-9

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. by Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP and Lahiri SD published in J. Antimicrob. Chemother. 2014; 69 (8): 2065-2075

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189

Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method. by Ross JE, Mendes RE and Jones RN published in J. Clin. Microbiol. 2014; 52 (9): 3399-3401

Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies. by Farrell DJ, Mendes RE, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (9): 5547-5551

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2014; 18 (2): 187-195

Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (5): 2921-2924

Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012). by Sader HS, Mendes RE, Farrell DJ, Flamm RK and Jones RN published in Pediatr. Infect. Dis. J. 2014; 33 (8): 837-842

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286

Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539